scholarly journals Association Study of BIF-1 Gene Expression with Histopathological Characteristics and Hormone Receptors in Breast Cancer

2021 ◽  
Author(s):  
Kazhaleh Mohammadi ◽  
Mahdiyeh Salimi ◽  
S. Abdolhamid Angaji ◽  
Arthur Saniotis ◽  
Foroozandeh Mahjoobi
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cancer Patients ◽  
Hormone Receptor ◽  
Hormone Receptors ◽  
Prognostic Significance ◽  
Her2 Status ◽  
Breast Cancer Patients ◽  
Bax Protein ◽  
The Relationship

Abstract Background Breast cancer (BC) is a heterogeneous disease that has different clinical outcomes. Bax-interacting Factor-1 (BIF-1) is a member of the endophilin B family that produces the pro-apoptotic BCL2-Associated X (BAX) protein in response to apoptotic signals. Lack of BIF-1 inhibits the intrinsic pathway of apoptosis and increases the risk of tumor genesis. The aim of the present study was to investigate the relationship between hormone receptors (ER, PR, HER2) status and different levels of BIF-1 gene expression in breast cancer patients. Methods BIF-1 gene expression was evaluated in 50 breast cancer tumors and 50 normal breast mammary tissues using SYBR Green Real Time RT-PCR technique. Multivariate and univariate analyses were used to evaluate the relationship between the prognostic significance of the BIF-1 gene using SPSS software. In this study, BIF-1 was selected as a candidate for a molecular biomarker and its expression status in breast cancer patients with hormone receptors (ER, RR, HER2) compared to patients without these hormone receptors. Results The study showed that the relative expression of BIF-1 gene in tissues of patients with hormone receptor in breast cancer compared to those without hormone receptor were not statistically significant. The expression levels of BIF-1 gene in different groups were evaluated for hormone receptor status. No significant relationship was found between BIF-1 gene expression and hormone receptors (ER, PR and HER2) (p> 0.05). Conclusion BIF-1 gene expression may be a useful prognostic marker in breast cancer.

scholarly journals Hormone Receptor-Status Prediction in Breast Cancer Using Gene Expression Profiles and Their Macroscopic Landscape

Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1165
Author(s):  
Seokhyun Yoon ◽  
Hye Sung Won ◽  
Keunsoo Kang ◽  
Kexin Qiu ◽  
Woong June Park ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cancer Patients ◽  
Hormone Receptor ◽  
Expression Profiles ◽  
Receptor Expression ◽  
Luminal Breast Cancer ◽  
Breast Cancer Patients ◽  
Intrinsic Subtypes ◽  
Receptor Status

The cost of next-generation sequencing technologies is rapidly declining, making RNA-seq-based gene expression profiling (GEP) an affordable technique for predicting receptor expression status and intrinsic subtypes in breast cancer patients. Based on the expression levels of co-expressed genes, GEP-based receptor-status prediction can classify clinical subtypes more accurately than can immunohistochemistry (IHC). Using data from The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA BRCA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) datasets, we identified common predictor genes found in both datasets and performed receptor-status prediction based on these genes. By assessing the survival outcomes of patients classified using GEP- or IHC-based receptor status, we compared the prognostic value of the two methods. We found that GEP-based HR prediction provided higher concordance with the intrinsic subtypes and a stronger association with treatment outcomes than did IHC-based hormone receptor (HR) status. GEP-based prediction improved the identification of patients who could benefit from hormone therapy, even in patients with non-luminal breast cancer. We also confirmed that non-matching subgroup classification affected the survival of breast cancer patients and that this could be largely overcome by GEP-based receptor-status prediction. In conclusion, GEP-based prediction provides more reliable classification of HR status, improving therapeutic decision making for breast cancer patients.

scholarly journals ASSOCIATION OF HORMONE RECEPTORS WITH RISK FACTORS AMONG BREAST CANCER PATIENTS

2021 ◽  
Vol 71 (Suppl-1) ◽  
pp. S118-22
Author(s):  
Ummara Aslam ◽  
Sarah Sadiq ◽  
Naseem Irshad ◽  
Ambreen Sadiq ◽  
Rabia Hamid
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Marital Status ◽  
Cancer Patients ◽  
Breast Feeding ◽  
Hormone Receptors ◽  
Her2 Status ◽  
Breast Cancer Patients ◽  
Cross Sectional ◽  
Co Morbidity

Objective: To compare the risk factors with estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status of breast cancer patients. Study Design: Cross sectional comparative study. Place and Duration of Study: This study was carried out in Multidisciplinary Lab-1 of Army Medical College,National University of Medical Sciences, Rawalpindi, in collaboration with Department of Pathology of ArmyMedical College, NUMS Rawalpindi, from Jan 2019 to Jan 2020. Methodology: A total of 50 individuals including radiologically diagnosed cases of breast cancer with differentstages and 10 healthy controls without cancer. Patients with any co-morbidity were excluded. Participant’ssample was collected and subjected to ER, PR and HER2 estimation. Other factors i.e. age, gender, marital status, breast feeding, menopause status, side of the breast affected were all taken into consideration. Results: Patients characteristics showed that the mean age, marital and menopause status were linked with breast cancer. The data showed that hormone receptors i.e., ER (p=0.0001), PR (p=0.0002) and HER2 (p=0.0001) were positive among most of the cancer patients as compared to the healthy subjects without cancer. There were no association found between age and hormone receptors. Marital status, breast feeding, menopause and side of breasts involved also had no association with hormone receptors. Conclusion: No significant association found between risk factors and hormone recpetors status of breast cancer patients in our population.

scholarly journals LMD-09. Outcomes and symptom benefit from palliative radiotherapy for leptomeningeal disease in breast cancer patients

2021 ◽  
Vol 3 (Supplement_3) ◽  
pp. iii9-iii9
Author(s):  
Jamie Takayesu ◽  
Eli Sapir ◽  
Jiaheng Xie ◽  
Yilun Sun ◽  
Aki Morikawa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hormone Receptor ◽  
Multivariate Logistic Regression Model ◽  
Her2 Status ◽  
Symptom Improvement ◽  
Intrathecal Therapy ◽  
Leptomeningeal Disease ◽  
Breast Cancer Patients ◽  
Improvement Rate

Abstract Objective The benefit of radiotherapy (RT) in patients with leptomeningeal disease (LMD) is poorly characterized. This study assessed the overall survival (OS) and clinical improvement of a largely symptomatic cohort of breast cancer patients with LMD, to identify patient subsets most likely to benefit from palliative RT. Methods Patients with breast cancer-related classic radiographic LMD (36% cytology-confirmed) were treated with palliative whole brain and/or partial spine RT between 2000–2020 at a single academic institution in this retrospective analysis. OS was calculated from date of LMD diagnosis using the Kaplan-Meier method. A multivariate logistic regression model incorporating ER/PR status, HER2 status, ECOG and steroid use was developed to identify factors associated with symptom benefit, which was ascertained retrospectively by chart review. Results Among 64 patients, the radiographic distribution of LMD was in the brain (58%), spine (22%), or both (20%). A total of 63% had brain metastases, and 57% of patients had ER+ and/or PR+, 22% HER2+, and 38% triple-negative disease. Of the symptomatic patients (94%), primary symptom domains included cranial nerve deficits (34%), sensory/motor deficits from intracranial disease (25%) or spinal disease (27%), and headaches/nausea (14%), with 42% of patients reporting >1 symptom domain. Two-thirds of patients were on steroids prior to RT, and 13% of patients received intrathecal therapy. OS was 3.75 months. Following a median dose of 30Gy in 10 fractions, 59% of symptomatic patients experienced symptom improvement, with similar improvement rate across domains (12%, 15%, 19%, 14%, respectively); 21% of patients had improvement in >1 symptom domain. Hormone receptor positivity was independently associated with symptom improvement following RT (OR 3.5, 95% CI 1.2–11, p=0.029). Conclusions In this poor-prognosis cohort of breast cancer patients with LMD, palliative RT yielded symptomatic improvement, and may be particularly beneficial among better-prognosis patients with hormone receptor-positive disease.

Sign in / Sign up

Export Citation Format

Share Document